CD155在恶性肿瘤中的免疫调控作用研究进展  

Research Progress on the Immunoregulatory Role of CD155 in Malignant Tumors

作　　者：刘雪[1] 郭凌川[2] Liu Xue;Guo Lingchuan(Department of Oncology,The First Affiliated Hospital of Soochow University,Suzhou 215000,Jiangsu,China;Department of Pathology,The First Affiliated Hospital of Soochow University,Suzhou 215000,Jiangsu,China)

机构地区：[1]苏州大学附属第一医院肿瘤科,苏州215000 [2]苏州大学附属第一医院病理科,苏州215000

出　　处：《哈尔滨医药》2023年第2期127-130,共4页Harbin Medical Journal

基　　金：苏州大学横向课题(H211353)。

摘　　要：CD155是免疫球蛋白超家族中的一种糖蛋白,在多种恶性肿瘤细胞中表达上调并与患者预后相关。近年来,CD155在肿瘤中的免疫调控作用吸引了广泛关注。CD155可与共刺激受体(CD226)和共抑制性受体(TIGIT和CD96)相互作用调节肿瘤浸润淋巴细胞功能。阻断CD155信号的免疫治疗有望改善肿瘤患者的预后,具有很大的临床应用潜力。本文将从CD155与恶性肿瘤患者预后的关系、免疫调控作用和相关免疫治疗等方面对CD155研究进展进行综述。CD155,a glycoprotein of immunoglobulin superfamily,is up-regulated in a variety of malignant tumor cells and associated with patient prognosis.Recently,the immunoregulatory role of CD155 has attracted extensive attention in tumors.CD155 could interact with co-stimulatory receptors(CD226)and co-inhibitory receptors(TIGIT and CD96),regulating function of tumor infiltrating lymphocytes.Immunotherapy of targeting CD155 signaling is expected to improve the prognosis of tumor patients and has great potential for clinical application.This article will review the research progress of CD155 from the aspects of the relationship between CD155 and the prognosis of malignant tumor patients,immunoregulatory role and related immunotherapy.

关 键 词：CD155 CD226 TIGIT CD96 恶性肿瘤 免疫治疗 

分 类 号：R730.4[医药卫生—肿瘤]